Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy

Clinical and Experimental Rheumatology

Volumn 23, Issue 2, 2005, Pages 247-250

  Favalli, Ennio Giulio ^a,b   Varenna, Massimo ^a   Sinigaglia, Luigi ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b NONE   (Italy)

Author keywords

Agranulocytosis; Autoimmunity; Infliximab; Neutropenia; Spondyloarthropathy

Indexed keywords

GRANULOCYTE ANTIBODY; HLA B27 ANTIGEN; INFLIXIMAB; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGRANULOCYTOSIS; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CAUCASIAN; CROHN DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; IMMUNOASSAY; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; SPONDYLOARTHROPATHY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; AUTOIMMUNITY; CROHN DISEASE; FILGRASTIM; HUMANS; MALE; NEUTROPENIA; SPONDYLARTHROPATHIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18644384159     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Van der KLAUW MM, GAUDSMIT R, HALIE MR et al.: A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159: 369-74.
2. FAVALLI EG, SINIGAGLIA L, VARENNA M, ARNOLDI C: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002; 11: 753-5.
3. PATTON WN, DUFFULL SB: Idiosyncratic drug-induced haematological abnormalities: incidence, pathogenesis, management, and avoidance. Drug Safety 1994; 11: 445-62.
4. BÉNICHOU C, SOLAL-CELIGNY P: Standardization of definitions and criteria for causality assessment of adverse drug reaction. Drug-induced blood cytopenias: report of an international consensus meeting. Nouvelle Revue Francaise d'Hematologie 1993; 33: 257-62.
5. ANDRÈS E, KURTZ JE, MALOISEL F: Non-chemotherapy drug-induced agranulocytosis: experience of the Strasbourgh teaching hospital (1985-2000) and review of the literature. Clin Lab Haematol 2002; 24: 99-106.
6. ANDRÈS E, KURTZ JE, PERRIN AE: The use of haematopoietic growth factors in antithyroid-related drug-induced agranulocytosis: a report of 20 patients. Q J Med 2001; 94: 423-8.
7. KAVENAUGH A, KEYSTONE EC: The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S203-S208.
8. ANTONI C, BRAUN J: Side effects of anti-TNF therapy: Current knowledge. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S152-S157.
9. TAJIRI J, NOGUCHI S, MURAKAMI T et al.: Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150: 621-4.
10. RUDOVIC R, JELIC S: Haematological aspects of drug-induced agranulocytosis. Scand J Haematatol 1972; 9: 18-27.
11. DALE DC, GUERRY D IV, WEWERKA JR et al.: Chronic neutropenia. Medicine 1979; 58: 128-44.
12. CLAAS FHJ: Immune mechanisms leading to drug-induced blood dyscrasias. Eur J Haematol 1996; 57 (Suppl.): 64-8.
13. GUEST I, UETRECHT J: Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix. Medical Hypotheses 1999; 53: 145-51.
14. DALE DC: Immune and idiopathic neutropenia. Curr Opin Haematol 1998; 5: 33-8.
15. YOUNG NS: Drug-related blood dyscrasias. Eur J Haematatol 1996; 60 (Suppl.): 6-8.
16. NYFELER B, PICHLER WJ: The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27: 175-81.
17. SAFFERMAN AZ, LIEBERMAN JA, ALVIR JMJ et al.: Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339: 1296-7.
18. CHARLES PJ, SMEENK RJT, De JONG J, FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 2000; 43: 2383-90.
19. LOUIS M, RAUCH J, ARMSTRONG M, FITZCHARLES M-A: Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003; 30: 2557-62.
20. CALABRESE LH: Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2001; 21: 241-8.
21. St CLAIR EW, WAGNER CL, FASANMADE AA et al.: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum 2002; 46: 1451-9.
22. SMITH MA, SMITH JG: Clinical experience with the use of rhG-CSF in secondary autoimmune neutropenia. Clin Lab Haematol 2002; 24: 93-7.